Kala Pharmaceuticals to Present at 2020 Wedbush PacGrow Healthcare Virtual Conference
August 04 2020 - 8:00AM
Business Wire
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical
company focused on the discovery, development and commercialization
of innovative therapies for diseases of the eye, today announced
that it will present at the 2020 Wedbush PacGrow Healthcare Virtual
Conference. Todd Bazemore, Chief Operating Officer of Kala
Pharmaceuticals, is scheduled to present on Tuesday, August 11,
2020 at 1:10 p.m. ET.
To access a live webcast and subsequent archived recording of
the presentation, please visit the “Investors & Media” section
on the Kala website at http://kalarx.com
About Kala Pharmaceuticals, Inc.
Kala is a biopharmaceutical company focused on the discovery,
development and commercialization of innovative therapies for
diseases of the eye. Kala has applied its AMPPLIFYTM mucus
penetrating particle Drug Delivery Technology to a corticosteroid,
loteprednol etabonate (LE), designed for ocular applications,
resulting in the January 2019 launch of INVELTYS® (loteprednol
etabonate ophthalmic suspension) 1% and its investigational product
candidate, EYSUVISTM (loteprednol etabonate ophthalmic suspension)
0.25%, for which a New Drug Application (NDA) is under review by
the United States Food and Drug Administration (FDA) with a
Prescription Drug User Fee Act (PDUFA) goal date set for October
30, 2020.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200804005087/en/
Investor Contact: Hannah Deresiewicz
hannah.deresiewicz@sternir.com 212-362-1200
KALA BIO (NASDAQ:KALA)
Historical Stock Chart
From Jun 2024 to Jul 2024
KALA BIO (NASDAQ:KALA)
Historical Stock Chart
From Jul 2023 to Jul 2024